Literature DB >> 25207144

Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections.

Fatma Banu Karahasanoğlu1, Ali Asan2, Suzan Sacar1, Hüseyin Turgut1.   

Abstract

BACKGROUND: Few studies have addressed the indirect costs of chronic hepatitis B and C, and none has assessed the real costs of these conditions, including indirect costs caused by loss of work, in Turkey. AIMS: This study therefore analysed the costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections to the community. STUDY
DESIGN: Cross-sectional study.
METHODS: This study analysed patients with chronic hepatitis B and hepatitis C treated at Pamukkale University Hospital Infectious Diseases and Clinical Microbiology Clinic, Denizli, Turkey between June 2009 and June 2010. Costs of antiviral treatment and follow-up were calculated from patients' medical records, and indirect costs were analysed from questionnaires completed by patients.
RESULTS: Data were analysed for 284 patients with chronic viral hepatitis. Indirect, hospital, treatment and total expenses were significantly higher for patients with chronic hepatitis B than for inactive hepatitis B virus carriers and patients with chronic hepatitis C. Hospital and total expenses of patients with complications were significantly higher than for patients with chronic hepatitis C. Hospital and total expenses were significantly higher for patients with than for individuals without cirrhosis. Indirect, hospital, treatment and total costs of patients were significantly higher for patients receiving combination therapy than monotherapy.
CONCLUSION: Reducing the costs to society of chronic hepatitis requires the development of protection and screening programs.

Entities:  

Keywords:  Cost; chronic hepatitis B; chronic hepatitis C

Year:  2013        PMID: 25207144      PMCID: PMC4115953          DOI: 10.5152/balkanmedj.2013.7547

Source DB:  PubMed          Journal:  Balkan Med J        ISSN: 2146-3123            Impact factor:   2.021


  18 in total

1.  Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.

Authors:  Sean D Sullivan; David L Veenstra; Pei-Jer Chen; Ting-Tsung Chang; Wan-Long Chuang; Chiaming Tsai; Kavita Patel
Journal:  J Gastroenterol Hepatol       Date:  2007-09       Impact factor: 4.029

Review 2.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

3.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

Review 4.  Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

Authors:  John B Wong
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs.

Authors:  Jun Su; Richard A Brook; Nathan L Kleinman; Patricia Corey-Lisle
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

6.  Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.

Authors:  W R Kim; J J Poterucha; J E Hermans; T M Therneau; E R Dickson; R W Evans; J B Gross
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

7.  A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore.

Authors:  Shu C Li; Siew C Ong; Sien C Ong; Seng G Lim; Khay G Yeoh; Kai S Kwong; Vivian Lee; Winnie Lee; Joseph Lau; Ian Wong; Nelson Kung; Wai T Leung; Henry L Y Chan; Francis K L Chan; Joseph J Y Sung; Kenneth K C Lee
Journal:  J Clin Gastroenterol       Date:  2004 Nov-Dec       Impact factor: 3.062

Review 8.  Epidemiology and natural history of hepatitis B.

Authors:  Brian J McMahon
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

9.  Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

Authors:  Joshua A Salomon; Milton C Weinstein; James K Hammitt; Sue J Goldie
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

10.  Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

Authors:  Maria Buti; Max Brosa; Miguel A Casado; Magdalena Rueda; Rafael Esteban
Journal:  J Hepatol       Date:  2009-05-20       Impact factor: 25.083

View more
  3 in total

1.  Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence.

Authors:  Sudip Bhattacharya; Özden Gökdemir; Md Abu Bashar; Arulmani Thiyagarajan; Amarjeet Singh
Journal:  Indian J Community Med       Date:  2021-03-01

2.  Response Guided Interferon Therapy for Genotype 3 of Chronic Hepatitis C: Compliance and Outcome.

Authors:  Shahid Sarwar; Anwaar A Khan; Shandana Tarique
Journal:  Pak J Med Sci       Date:  2015 Jul-Aug       Impact factor: 1.088

3.  Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey.

Authors:  Guvenc Kockaya; Akin Kose; Fatma Betul Yenilmez; Oktay Ozdemir; Ece Kucuksayrac
Journal:  Cost Eff Resour Alloc       Date:  2015-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.